Clinical Trial Details
Braintumor Website

[Information provided by: ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT03098732 : Magnetically Enhanced Diffusion for Acute Ischaemic Stroke (MEDIS) Trial
PhaseN/A
AgesMin: 18 Years Max: 85 Years
Eligibility
Inclusion Criteria:

1. Age ?18 and <85

2. Clinical signs consistent with acute ischaemic stroke

3. Prestroke functional independence (prestroke Modified Rankin Score ?2)

4. NIHSS 4-25 at the time of randomisation

5. Initiation of IV tPA (alteplase or tissue Plasminogen Activator) within the locally
approved time window from stroke symptom onset (onset time is defined as the last
time when the subject was witnessed to be at baseline).

6. Arterial Occlusive Lesion (mAOL ?1) in the M1 or M2 segments of the MCA (Middle
Cerebral Artery) or carotid terminus confirmed by CT angiography.

7. Subject is able to start the MED procedure within 15 +10 minutes) from the t-PA IV
infusion, and complete 60+15 minutes of MED procedure treatment.

8. Subject or subject's legally authorised representative has signed and dated an
Informed Consent Form according to country regulations, ethics committee, and/or
Institutional Review Board requirements.

9. It is the enrolling Investigator's or designee's opinion based upon the knowledge of
the Subject's condition as well as the features of the MED device, that the Subject
is an appropriate candidate for stroke management utilizing MED.

Exclusion Criteria:

1. The subject is likely to receive intra-arterial (IA) intervention.

2. Standard exclusions for thrombolysis according to the approved label and local
institutional protocols.

3. Female who is pregnant or lactating or has a positive pregnancy test at time of
admission.

4. Rapid neurological improvement prior to study randomisation suggesting resolution of
the occlusion.

5. Known hyper-sensitivity to radiographic contrast agents.

6. Known hyper-sensitivity to iron-based agents or polyethylene glycol.

7. Known or suspected symptomatic haemosiderosis or haemochromatosis.

8. Has a previous or existing cardiovascular condition resulting in history of heart
block, tachybrady syndrome, symptomatic postural hypotension requiring medical
intervention.

9. Current participation or participation in the last 4 weeks in another investigational
drug or device treatment study.

10. Life expectancy of less than 90 days due to other medical condition.

11. Subject with a pre?existing neurological or psychiatric disease that would confound
the neurological and functional evaluations.

12. Subject has contraindications to Magnetic Resonance Imaging (MR; examples include,
but are not limited to, an implantable cardioverter defibrillator, pacemaker, clipped
or coiled aneurysm, neurostimulator).

13. Subject has recently (within 30 days) received iron replacement therapy or iron based
MR contrast.

14. Subject has known or suspected liver disease, including hepatitis and/or cirrhosis.

Imaging Exclusion Criteria:

1. Computed tomography (CT) or MRI evidence of haemorrhage on presentation.

2. Exclusion: Large core of ischemia defined as NCCT ASPECTS 4 or less.

3. CT or MRI evidence of mass effect or intra?cranial tumour (except small meningioma).

4. CTA or MRA (CT or MR Angiography) evidence of carotid dissection or complete cervical
carotid occlusion.
LinksPermanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT03098732      |      Link to official Clinicaltrials.gov listing
Locations



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740